By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Investment firm Mizuho initiated coverage of Myriad Genetics on Thursday, calling the Salt Lake City firm "the crown jewel in personalized medicine."

In a report, analyst Peter Lawson initiated coverage with an "outperform" rating and a 12-month target share price of $25, or about 22 percent above the current stock price.

On Thursday, Myriad shares closed at $20.83.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.

Sponsored by

This webinar will address a range of methods for optimizing small RNA library preparation.

Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

Sponsored by

This webinar will discuss how understanding the relative performance characteristics of glass and polymer substrates for in vitro diagnostic applications such as microarrays and microfluidics can help to optimize diagnostic performance.